908 POSTER A Randomised phase II study of phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Taxane Chemotherapy

Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5585 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5585-5585 ◽

Cited By ~ 2

Author(s):

Kristen Paige Bunch ◽

Anne M. Noonan ◽

Jung-min Lee ◽

Ciara Catherine Maria O'Sullivan ◽

Nicole D. Houston ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Pharmacodynamic Biomarkers

A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5571 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5571-5571 ◽

Cited By ~ 5

Author(s):

Erika Paige Hamilton ◽

Michael J. Birrer ◽

Brian Anthony DiCarlo ◽

Stephanie Gaillard ◽

Lainie P. Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Multicenter Study ◽

Open Label ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Phase 1B

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.06.019 ◽

2011 ◽

Vol 123 (1) ◽

pp. 33-36 ◽

Cited By ~ 35

Author(s):

Lubomir Bodnar ◽

Maria Górnas ◽

Cezary Szczylik

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Peritoneal Cancer ◽

Line Therapy ◽

Third Line Therapy ◽

Third Line

Efficacy of second line chemotherapeutic regimens in persistent or recurrent epithelial ovarian cancer including fallopian tube cancer and primary peritoneal cancer: A multicenter retrospective study

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.04.546 ◽

2019 ◽

Vol 154 ◽

pp. 235-236

Author(s):

H.P. Lee ◽

Y.B. Kim

Keyword(s):

Ovarian Cancer ◽

Retrospective Study ◽

Fallopian Tube ◽

Second Line ◽

Fallopian Tube Cancer ◽

FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.062 ◽

2017 ◽

Vol 28 ◽

pp. v353

Author(s):

K.N. Moore ◽

I. Vergote ◽

A. Oaknin ◽

N. Colombo ◽

S. Banerjee ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Folate Receptor ◽

Phase 3 ◽

Fallopian Tube Cancer ◽

Safety And Efficacy ◽

Peritoneal Cancer ◽

Receptor Alpha

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.017 ◽

2011 ◽

Vol 2011 ◽

pp. 78-79

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Clinical Activity ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Abstract CT091: Phase I study of intraperitoneal TRX-E-002-1 in patients with persistent or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Results of dose-escalation phase

10.1158/1538-7445.am2019-ct091 ◽

2019 ◽

Author(s):

Jermaine Coward ◽

Don Dizon ◽

Ganessan Kichenadasse ◽

Paul Harnett ◽

Kathleen Moore ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Fallopian Tube ◽

Dose Escalation ◽

Phase I Study ◽

Recurrent Ovarian Cancer ◽

Fallopian Tube Cancer ◽

Abstract CT091: Phase I study of intraperitoneal TRX-E-002-1 in patients with persistent or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Results of dose-escalation phase

10.1158/1538-7445.sabcs18-ct091 ◽

2019 ◽

Author(s):

Jermaine Coward ◽

Don Dizon ◽

Ganessan Kichenadasse ◽

Paul Harnett ◽

Kathleen Moore ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Fallopian Tube ◽

Dose Escalation ◽

Phase I Study ◽

Recurrent Ovarian Cancer ◽

Fallopian Tube Cancer ◽

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

Platinum Resistant

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5009 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5009-5009 ◽

Cited By ~ 36

Author(s):

R. A. Burger ◽

M. Sill ◽

B. J. Monk ◽

B. Greer ◽

J. Sorosky

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽